

June 19, 2020

To,
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sir,

Sub: Glenmark Pharmaceuticals receives ANDA approval for Fingolimod Capsules, 0.5 mg

With reference to the subject mentioned above, kindly find attached media release which is self explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

**HARISH
VINAYAK KUBER**

Digitally signed by HARISH VINAYAK KUBER
DN: c=IN, st=Maharashtra,
2.5.4.20=cde2956f5be913821f9991026d376afdaebf5b8838c3a7
1de2e75255a782d, postalCode=400049, street=C21, Maker
Kundan Garden,
serialNumber=afbac799832e525179ba4771e8bf676e0e3cac49
1160c0271c804b16e4f, o=Personal, cn=HARISH VINAYAK KUBER
Date: 2020.06.19 10:20:59 +05'30'

Harish Kuber
Company Secretary & Compliance Officer

Encl: as above

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Press Release

For Immediate Release

Glenmark Pharmaceuticals receives ANDA approval for Fingolimod Capsules, 0.5 mg

Mumbai, India; June 19, 2020: Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya®¹ Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.

According to IQVIA™ sales data for the 12 month period ending April 2020, the Gilenya® Capsules, 0.5 mg market² achieved annual sales of approximately \$2.1 billion*.

Glenmark's current portfolio consists of 164 products authorized for distribution in the U.S. marketplace and 44 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

—End—

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). For more information, visit www.glenmarkpharma.com

For more information:

Glenmark Media Contact

Madhurima Gupta Jain

Glenmark Pharmaceuticals, Mumbai, India

Tel: +91 22 4018 9606

Email: corpcomm@glenmarkpharma.com

¹All brand names and trademarks are the property of their respective owners.

²Market includes brand and all available therapeutic equivalents

*IQVIA™ National Sales Perspectives: Retail & Non-Retail, April 2020